Related Experiment Video
Updated: Jun 19, 2026

A Tetracycline-regulated Cell Line Produces High-titer Lentiviral Vectors that Specifically Target Dendritic Cells
Published on: June 19, 2013
Lentiviral vectors in clinical trials: Current status
Jenice D'Costa1, S Gary Mansfield, Laurent M Humeau
1VIRxSYS Corp, Gaithersburg, MD 20877, USA.
Abstract:
Lentiviral vectors (LVs) are the most recently developed viral-derived vectors for gene therapy applications, and have demonstrated much promise. The ability to transduce dividing and non-dividing cells, and sustain long-term transgene expression makes LVs uniquely desirable as gene therapy vectors. With advances in vector design and large-scale production, LVs have become safer and more effective gene delivery systems. Since the first clinical trial was approved in 2002, several trials to treat patients with both infectious and genetic diseases have been approved. This review focuses on ongoing and planned trials of LV-based gene therapy.
More Related Videos
11:08Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
Published on: April 8, 2012
13:47Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
Published on: March 29, 2019
Related Concept Videos
Clinical Trials: Overview
Microorganisms in Medicine and Therapeutics
Clinical Trials
There are four phases in a clinical trial. A phase one...
Preclinical Development: Overview
Gene Therapy